STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review)

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1181-1191

  Wang, Xiaochun ^a,b   Crowe, Philip J ^b   Goldstein, David ^b   Yang, Jia Lin ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer therapy; Constitutive activation of STAT3; STAT3 inhibition; STAT3 inhibitor clinical trials; STAT3 related microRNA

Indexed keywords

515 DPP; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; COMPLEMENTARY RNA; DASATINIB; INCB 20; LLL 12; LLL12; MICRORNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NSC 74859; OPB 31121; RNA; S3I201; S3IM2001; SMALL INTERFERING RNA; STAT3 PROTEIN; STX 0119; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CLINICAL RESEARCH; DRUG TARGETING; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA, ANTISENSE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84866490114     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1568     Document Type: Article

References (140)

1. Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749, 2002.
2. Darnell JE: STATs and gene regulation. Science 277: 1630-1635, 1997.
3. Bromberg J and Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2000.
4. Ihle JN: STATs: signal transducers and activators of transcription. Cell 84: 331-334, 1996.
5. Herrington J, Smit LS, Schwartz J and Carter-Su C: The role of STAT proteins in growth hormone signaling. Oncogene 19: 2585-2597, 2000.
6. Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
7. Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J and Clifford JL: Active Stat3 is required for survival of human squamous cell carcimoma cells in serum-free conditions. Mol Cancer 5: 15, 2006.
8. Kusaba T, Nakayama T, Yamazumi K, et al: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15: 1445-1451, 2006.
9. Morikawa T, Baba Y, Yamauchi M, et al: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17: 1452-1462, 2011.
10. de la Iglesia N, Konopka G, Lim KL, et al: Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28: 5870-5878, 2008.
11. de la Iglesia N, Konopka G, Puram SV, et al: Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22: 449-462, 2008.
12. Copeland NG, Gilbert DJ, Schindler C, et al: Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29: 225-228, 1995.
13. Lai SY and Johnson FM: Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 13: 67-78, 2010.
14. Quesnelle KM, Boehm AL and Grandis JR: STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319, 2007.
15. Gao L, Zhang L, Hu J, et al: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11: 6333-6341, 2005.
16. Kisseleva T, Bhattacharya S, Braunstein J and Schindler CW: Sigaling through the JAK-STAT pathway, recent advances and future challenges. Gene 285: 1-24, 2002.
17. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal tansducer and activator of transcription-3, inflammation, and cancer. Ann NY Acad Sci 1171: 59-76, 2009.
18. Pawson T, Gish GD and Nash P: SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 11: 504-511, 2001.
19. Zhong Z, Wen Z and Darnell JE: Stat3, a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
20. Leeman R, Lui VWY and Grandis JR: STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6: 231-241, 2006.
21. Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94: 3801-3804, 1997.
22. Yang XO, Panopoulos AD, Nurieva R, et al: STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282: 9358-9363, 2007.
23. Miyoshi K, Takaishi M, Nakajima K, et al: Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 131: 108-117, 2011.
24. Zhang HY, Zhang Q, Zhang X, et al: Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 300: G454-G460, 2011.
25. Mora LB, Buettner R, Seigne J, et al: Constitutive activation of Atat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
26. Burger R, Le Gouill S, Tai Y-T, et al: Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 8: 26-35, 2009.
27. Wei L-H, Kuo M-L, Chen C-A, et al: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517-1527, 2003.
28. Lopiccolo J, Blumenthal G, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50, 2008.
29. Sasse J, Hemmann U, Schwartz C, et al: Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol 17: 4677-4686, 1997.
30. Shuai K, Horvath CM, Huang LHT, Qureshi S, Cowburn D and Darnell JE: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76: 821-828, 1994.
31. Fletcher S and Gunning PT: Mild, efficient and rapid O-debenzylation of ortho-substituted phenols with trifluoroacetic acid. Tetrahedron Lett 49: 4817-4819, 2008.
32. Yu C-L, Meyer DJ, Campbell GS, et al: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83, 1995.
33. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H and Wilson MB: Control of myeloid differentiation and survial by Stats. Oncogene 19: 2612-2618, 2000.
34. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
35. Catlett-Falcone R, Dalton WS and Jove R: STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 11: 490-496, 1999.
36. Inamura K, Matsuzaki Y, Uematsu N, Hondab A, Tanaka N and Uchida K: Rapid inhibition of MAPK signaling and antiproliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745: 401-410, 2005.
37. Yang JL, Zahorowska B, Kasim Y, Goldstein D and Crowe P: Mechanism of the synergistic antiproliferative effect of gefitinib and interferon-alpha in sarcoma cell lines. Proc 101st Ann Meet AACR 398-399 (abs. 1655), 2010.
38. Turkson J and Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000.
39. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
40. Aggarwal BB, Sethi G, Ahn KS, et al: Targeting signal-transducer-and- activator-of-transcription-3 for prevention and therapy of cancer. Ann NY Acad Sci 1091: 151-169, 2006.
41. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q and Turkson J: A functional nuclear epidermal growth factor receptor, Src and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One 6: e19605, 2011.
42. Arany I, Chen S-H, Megyesi JK, et al: Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett 199: 83-89, 2003.
43. Masuda M, Suzui M, Yasumatu R, et al: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
44. Chun K-S and Langenbach R: The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin. Mol Carcinog 50: 439-448, 2011.
45. Grandis JR, Drenning SD, Zeng Q, et al: Contitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232, 2000.
46. Kijima T, Niwa H, Steinman RA, et al: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13: 355-362, 2002.
47. Huang M, Page C, Reynolds K and Lin J: Constitutive activation of Stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79: 67-73, 2000.
48. Niu G, Bowman T, HUang M, et al: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
49. Chen CL, Hsieh FC, Lieblein JC, et al: Stat3 activation in human endometrial and cervical cancers. Br J Cancer 96: 591-599, 2007.
50. + T cells is regulated by STAT3 and is pathologically involved in Sézary Syndrome. J Invest Dermatol 131: 762-768, 2010.
51. Loffler D, Brocke-Heidrich K, Pfeifer G, et al: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110: 1330-1333, 2007.
52. Ahluwalia A, Busse BA, Thiruvengadam SS and Tarnawski AS: Importins are critical for colorectal cancer (CRC) growth a nd are novel biomarkers of CRC. Underlying mechanisms include: increased nuclear transport of P-CREB and p-STAT3, VEGF gene promoter activation and aberrant VEGF expression. Gastroenterology 140: S184, 2011.
53. Wei D, Le X, Zheng L, et al: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329, 2003.
54. Xu Q, Briggs J, Park S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560, 2005.
55. Xie T-X, Wei D, Liu M, et al: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560, 2004.
56. Dechow TN, Pedranzini L, Leitch A, et al: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101: 10602-10607, 2004.
57. Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Immunology 7: 41-51, 2007.
58. Kortylewski M, Kujawski M, Wang T, et al: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321, 2005.
59. Kortylewski M and Yu H: Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20: 228-233, 2008.
60. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
61. Garcia R, Bowman TL, Niu G, et al: Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001.
62. Nagpal JK, Mishra R and Das BR: Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 94: 2393-2400, 2002.
63. Deng J-Y, Sun D, Liu X-Y, Pan Y and Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 16: 5380-5387, 2010.
64. Watson CJ and Miller WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844, 1995.
65. Kosaka T, Yamaki E, Mogi A and Kuwano H: Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011: 1-7, 2011.
66. Himpe E and Kooijman R: Insulin-like growth factor-I receptor signal transduction and the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. Biofactors 35: 76-81, 2009.
67. Sporeno E, Savino R, Ciapponi L, et al: Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 87: 4510-4519, 1996.
68. Demartis A, Bernassola F, Savino R, Melino G and Ciliberto G: Interleukin 6 receptor superantagonists are potent inducers of human multiple. Cancer Res 56: 4213-4218, 1996.
69. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
70. Johnson FM, Saigal B, Talpaz M and Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932, 2005.
71. Perry E, Tsruya R, Levitsky P, et al: TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3. Oncogene 23: 8908-8919, 2004.
72. Gu Q, Kong Y, Yu Z-B, Bai L and Xiao Y-B: Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease. Biochimie 93: 909-920, 2011.
73. Ulane CM, Kentsis A, Cruz CD, Parisien J-P, Schneider KL and Horvath CM: Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. J Virol 79: 10180-10189, 2005.
74. Lesina M, Kurkowski Magdalena U, Ludes K, et al: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic Cancer. Cancer Cell 19: 456-469, 2011.
75. Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G and Riemenschneider MJ: SOCS3 promoter methylation methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 122: 241-251, 2011.
76. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R and Dowlati A: Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol 5: 256-264, 2011.
77. Migone T-S, Cacalano NA, Taylor N, Yi T, Waldmann TA and Johnston JA: Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 recepto; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci USA 95: 3845-3850, 1998.
78. Schaper F, Gendo C, ECK M, et al: Activation of the protein tyrosine phosphatease SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine Jak1 and limits acute-phase protein expression. Biochem J 355: 557-565, 1998.
79. Irie-Sasaki J, Sasaki T, Matsumoto W, et al: CD45 is a JAK phosphatase and negatively regulates cytokine recptor signalling. Nature 409: 349-354, 2001.
80. Sun S and Steinberg BM: PTEN is a negative regualtor of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 83: 1651-1658, 2002.
81. Desrivières S, Kunz C, Barash I, Vafaizadeh V, Borghouts C and Groner B: The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia 11: 75-87, 2006.
82. Scoles DR, Nguyen VD, Qin Y, et al: Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT singling. Hum Mol Genet 11: 3179-3189, 2002.
83. Bhasin D, Cisek K, Pandharkar T, et al: Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 18: 391-395, 2008.
84. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
85. Akao Y, Nakagawa Y and Naoe T: let-7 MicroRNA functions as a potential grwoth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906, 2006.
86. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
87. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
88. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
89. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
90. He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature 435: 828-833, 2005.
91. Foshay KM and Gallicano GI: miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol 326: 431-443, 2009.
92. Krichevsky AM, Sonntag K-C, Isacson O and Kosik KS: Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 24: 857-864, 2006.
93. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y and Patel T: The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 282: 8256-8264, 2007.
94. Niu G, Heller R, Catlett-Falcone R, et al: Gene therapy with dominant-negative Stat3 suprresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59: 5059-5063, 1999.
95. Niu G, Shain KH, Huang M, et al: Overexpression of a dominant-negative signal transducer and activator of trnascription 3 varian in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61: 3276-3280, 2001.
96. Mishra PJ and Merlino G: MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119: 2119-2123, 2009.
97. Liang Z-W, Guo B-F, Li Y, et al: Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo. Asian J Androl 13: 481-486, 2011.
98. Petrocca F and Lieberman J: Promise and chanllenge of RNA interference-based therapy for cancer. J Clin Oncol 29: 747-754, 2011.
99. Fletcher S, Drewry JA, Shahani VM, Page BDG and Gunning PT: Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 87: 825-833, 2009.
100. Turkson J, Ryan D, Kim JS, et al: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276: 45443-45455, 2001.
101. Turkson J, Kim JS, Zhang S, et al: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3: 261-269, 2004.
102. Siddiquee K, Zhang S, Guida WC, et al: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104: 7391-7396, 2007.
103. Lin L, Amin R, Gallicano GI, et al: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28: 961-972, 2009.
104. Hayakawa F, Sugimoto K, Kurahashi S, et al: A novel direct STAT3 inhibitor OPB-31121 induces tumor-specific growth inhibition in a wide4 range of hematopoietic malignacies and effectively suppresses the chemotherapy resistant quiescent cell in vivo. 52nd ASH Ann Meet & Expo III-56, 2010.
105. Lo H-W, Cao X, Zhu H and Ali-Osman F: Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and akylators. Clin Cancer Res 14: 6042-6054, 2008.
106. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618, 2002.
107. Oh D, Han S, Kim TM, et al: A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. J Clin Oncol 28: e13056, 2010.
108. Sartor CI, Dziubinski ML, Yu C-L, Jove R and Ethier SP: Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 57: 978-987, 1997.
109. Garcia R, Yu C-L, Hudnall A, et al: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8: 1267-1276, 1997.
110. Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165, 2003.
111. Haura EB, Zheng Z, Song L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294, 2005.
112. Gao SP, Mark KG, Leslie K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007.
113. Pfeiffer M, Hartmann T, Leick M, Catusse J, Schmitt-Graeff A and Burger M: Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer 100: 1949-1956, 2009.
114. Quintanilla-Martinez L, Kremer M, Specht K, et al: Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma, Stat3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162: 1449-1461, 2003.
115. Chen C-L, Loy A, Cen L, et al: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7: 111, 2007.
116. Grandis JR, Drenning SD, Chakraborty A, et al: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998.
117. Grandis JR, Zeng Q and Drenning SD: Epidermal growth factor receptor-mediated Stat3 singaling blocks apoptosis in head and neck cancer. Laryngoscope 110: 868-874, 2000.
118. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD and Gutkind JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcimoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130. Cancer Res 63: 2948-2956, 2003.
119. Ni Z, Lou W, Leman ES and Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228, 2000.
120. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ and Huang HF: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 1: 19, 2001.
121. DeMiguel F, Lee SO, Lou W, et al: Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52: 123-129, 2002.
122. Barton BE, Karras JG, Murphy TF, Barton A and Huang HF-S: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20, 2004.
123. Sanchez A, Nagy P and Thorgeirsson SS: STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 39: 2093-2098, 2003.
124. Dhir R, Ni Z, Lou W, De Miguel F, Grandis JR and Gao AC: Stat3 activation in prostatic carcinomas. Prostate 51: 241-246, 2002.
125. Sachez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A and Gutierrez-Castellanos S: Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 54: 163-168, 2006.
126. David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS and Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis. J Exp Clin Cancer Res 30: 56, 2011.
127. Niu G, Wright KL, Huang M, et al: Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
128. Gritsko T, Williams A, Turkson J, et al: Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19, 2006.
129. Gao L, Li F, Dong B, et al: Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. Intl J Radiat Oncol Biol Phys 77: 1223-1231, 2010.
130. Song H, Wang R, Wang S and Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102: 4700-4705, 2005.
131. Fuh B, Sobo M, Cen L, et al: LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 100: 106-112, 2009.
132. Schust J, Sperl B, Hollis A, Mayer TU and Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235-1242, 2006.
133. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79: 1398-1409, 2010.
134. Fletcher S, Singh J, Zhang X, et al: Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chem Biol Chem 10: 1959-1964, 2009.
135. Siddiquee KAZ, Gunning PT, Glenn M, et al: An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and incuces antitumor cell effects. ACS Chem Biol 2: 787-798, 2007.
136. Uehara Y, Mochizuki M, Matsuno K, Haino T and Asai A: Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem Biophys Res Commun 380: 627-631, 2009.
137. Ball S, Li C, Li P-K and Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 6: e18820, 2011.
138. Lin L, Hutzen B, Li P-K, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activites and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12: 39-50, 2010.
139. Matsuno K, Masuda Y, Uehara Y, et al: Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med Chem Lett 1: 371-375, 2010.
140. Ashizawa T, Miyata H, Ishii H, et al: Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 38: 1245-1252, 2011.